Skip to content

Hippo Holdings HIPO R&D credit carryforward

R&D credit carryforward at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$63.46M+1.8%
Richtech Robotics Inc. logo
Richtech Robotics Inc.RR
$7K0.0%
AZZ logo
AZZAZZ
$970K-80.8%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$6.91M-4.9%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$18.89M0.0%
HTF
Heartflow, Inc. Common StockHTFL
$7.63M+7.3%

Other financials

Income statement

See full
Revenue$121.5M+10.2%
Operating income-$561.6K
Net income$7.1M+115%
EPS (diluted)$0.27+114%

Balance sheet

See full
Cash & equivalents$304.8M+69.1%
Total debt$3.6M-59.6%
Total equity$448.7M+39.0%
Total assets$2.1B+33.9%

Cash flow

See full
Operating cash flow$8.5M+124%
CapEx$100.0K0.0%
Free cash flow$8.4M+124%

Valuation

See full
Market cap$673.55M-6.1%
Enterprise value$372.35M-31.8%
P/E
P/S1.4×-0.4×

Profitability

See full
Net margin23.4%
FCF margin11.1%

Returns & leverage

See full
Return on equity29.2%
Debt / equity0.0×
Current ratio0.7×

Where this comes from

Reported directly by Hippo Holdings in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: Hippo Holdings’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Hippo Holdings's r&d credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Hippo Holdings's r&d credit carryforward?
Hippo Holdings (HIPO) reported r&d credit carryforward of $11.9M in Q4 2025.
What does r&d credit carryforward mean?
This represents the accumulated value of research and development tax credits that have not yet been utilized to offset tax liabilities. These carryforwards serve as a future tax benefit that can reduce the company's effective tax rate in subsequent periods. It reflects the company's historical investment in innovation and product development.